Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Florzolotau (18F) retention is linked to neuropsychological performance in tauopathy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shimizu Atsushi, Iwabuchi Yu, Bun Shogyoku, Watanabe Memi, Kubota Masahito, Shimohama Sho, Tezuka Toshiki, Takahata Keisuke, Tabuchi Hajime, Seki Morinobu, Momota Yuki, Yamamoto Yasuharu, Shikimoto Ryo, Mimura Yu, Kurose Shin, Sakurai Ryosuke, Takayama Toshiki, Hoshino Yuka, Hoshino Takayuki, Suzuki Natsumi, Morimoto Ayaka, Osumi Azusa, Mimura Masaru, Jinzaki Masahiro, Ito Daisuke
Аннотация
INTRODUCTION: Florzolotau (18F) positron emission tomography visualizes three- and four-repeat tau isoforms. We aimed to evaluate correlation of tau tracer retention with neuropsychological performance across the Alzheimer's disease (AD) continuum and non-AD tauopathies.
METHODS: This study enrolled 178 patients with cognitive impairment and 60 volunteers. Participants were divided into AD continuum (n = 120) and non-AD tauopathy (n = 98) groups and assessed using the Mini-Mental State Examination (MMSE), Clinical Dementia Rating, Functional Activity Questionnaire, Wechsler Memory Scale-Revised Logical Memory, Alzheimer's Disease Assessment Scale Cognitive subscale, Trail Making Test (TMT), word fluency, and the Japanese Adult Reading Test. Voxel-based analysis was performed.
RESULTS: In the AD continuum group, all cognitive test performances significantly correlated with tracer uptake, particularly in the left cortical areas. In the non-AD tauopathy group, strong correlations were observed with MMSE and TMT Part B performance.
DISCUSSION: Neuropsychological performance and regional tau pathology distribution are correlated in patients with tauopathy, with differences between AD continuum and non-AD tauopathy.
CLINICAL TRIAL REGISTRATION: This trial is registered with UMIN Clinical Trials (UMIN-CTR number: 000032027); submitted for registration on March 30, 2018; first patient enrolment was on July 3, 2018.
METHODS: This study enrolled 178 patients with cognitive impairment and 60 volunteers. Participants were divided into AD continuum (n = 120) and non-AD tauopathy (n = 98) groups and assessed using the Mini-Mental State Examination (MMSE), Clinical Dementia Rating, Functional Activity Questionnaire, Wechsler Memory Scale-Revised Logical Memory, Alzheimer's Disease Assessment Scale Cognitive subscale, Trail Making Test (TMT), word fluency, and the Japanese Adult Reading Test. Voxel-based analysis was performed.
RESULTS: In the AD continuum group, all cognitive test performances significantly correlated with tracer uptake, particularly in the left cortical areas. In the non-AD tauopathy group, strong correlations were observed with MMSE and TMT Part B performance.
DISCUSSION: Neuropsychological performance and regional tau pathology distribution are correlated in patients with tauopathy, with differences between AD continuum and non-AD tauopathy.
CLINICAL TRIAL REGISTRATION: This trial is registered with UMIN Clinical Trials (UMIN-CTR number: 000032027); submitted for registration on March 30, 2018; first patient enrolment was on July 3, 2018.